GENEGLOBE
LIVE

Serial Number

78722164

Owner

QIAGEN GMBH

Attorney

Victoria Friedman

Filing Date

Sep 28, 2005

Add to watchlist:

No watchlists yet
View on USPTO

GENEGLOBE Trademark

Serial Number: 78722164 • Registration: 3297334

GENEGLOBE is a trademark filed by QIAGEN GMBH on September 28, 2005. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

QIAGEN GMBH (212 trademarks)

HILDEN D-4010 , DE

Entity Type: 03

Trademark Details

Filing Date

September 28, 2005

Registration Date

September 25, 2007

Published for Opposition

July 10, 2007

Goods & Services

[ Scientific apparatuses, instruments and equipment, namely, optical apparatuses and instruments, calculating machines, electrical and electronic apparatuses and instruments, in particular for research and analysis purposes, and laboratory equipment, measuring apparatuses and instruments, namely, robot manipulators, laboratory consumable dispensers, laboratory sample conditioners, namely, incubators, stirrers, mixers, dispensers, aspirators, laboratory and measuring apparatuses and instruments, filter systems for laboratory purposes, ultrafiltration devices and apparatuses, ultrafiltration membranes, chromatography apparatuses and instruments, ion exchanger apparatuses and instruments, laboratory concentrator devices, scientific apparatuses and instruments being laboratory equipment and single-use laboratory articles, in particular laboratory apparatuses for the processing of fluid samples, in particular apparatuses for dosing, transferring, mixing, tempering, concentrating, homogenizing and filtering of sample liquids and reagents for medical and veterinary medical diagnostic purposes, in particular for sample preparation, modification and manipulation of cells and for labeling, separation, isolation, reproduction and the purification of biopolymers, in particular nucleic acids, proteins, macromolecules and biologically active substances, in particular nucleic acids and proteins from biological material ]

Products for human medicine and veterinary medicine purposes, in particular diagnostic preparations, in particular for sample preparation, modification and manipulation of cells as well as for labeling, separation, isolation, reproduction and purification of biopolymers, in particular nucleic acids, proteins, macromolecules and biologically active substances; chemical biochemical and biotechnological products all for human medicine and veterinary medicine purposes, in particular reagents and solvents, in particular for sample preparation, modification and manipulation of cells as well as for the performance of labeling, separation, isolation, reproduction and purification methods for biopolymers, in particular nucleic acids, proteins, macromolecules and biologically active substances for diagnostic purposes; kits consisting primarily of siRNA compounds, protein assays and chemical reagents for human medicine or veterinary medicine diagnostic purposes, in particular for sample preparation, modification and manipulation of cells as well as for labeling, separation, isolation, reproduction and purification of biopolymers, in particular nucleic acids, proteins, macromolecules and biologically active substances, in particular nucleic acids and proteins from biological material

Diagnostic preparations, except for human medicine and veterinary medicine purposes; reagents and solvents not for human medical and veterinary purposes, in particular for sample preparation, modification and manipulation of cells as well as for the performance of labeling, separation, isolation, reproduction and purification methods for biopolymers, in particular nucleic acids, proteins, macromolecules and biologically active substances; kits consisting primarily of siRNA compounds, protein assays and chemical reagents, in particular for sample preparation, modification and manipulation of cells as well as for labeling, separation, isolation, reproduction and purification of biopolymers, in particular nucleic acids, proteins, macromolecules and biologically active substances, in particular nucleic acids and proteins from biological material

Scientific and technological services, namely, research, development and diagnostics in the field of cancer treatment and diagnosis, treatment and diagnosis of viral and bacterial mediated diseases, treatment and diagnosis of diseases of the blood, treatment and diagnosis of diseases of the skin, treatment and diagnosis of diseases of the brain, treatment and diagnosis of diseases of the heart, treatment and diagnosis of diseases of the liver, treatment and diagnosis of diseases of the lungs; as well as design services, namely, work on and evaluation of chemical syntheses, in particular the synthesis of oligonucleotides, polynucleotides and proteins

Filing History

TEAS CHANGE OF CORRESPONDENCE RECEIVED
May 3, 2024 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
May 3, 2024 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
May 3, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
May 3, 2024 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
May 3, 2024 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
May 3, 2024 COAR
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jul 21, 2021 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jul 21, 2021 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Jul 21, 2021 ECDR
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Jul 21, 2021 EWAF
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jul 21, 2021 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jul 21, 2021 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jul 21, 2021 COAR
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
Nov 15, 2017 NA89
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
Nov 15, 2017 RNL1
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
Nov 15, 2017 89AG
POST REGISTRATION ACTION MAILED - SEC. 8 & 9
Nov 7, 2017 PR89
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Oct 25, 2017 APRE
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
Sep 18, 2017 NA89
POST REGISTRATION ACTION CORRECTION
Sep 18, 2017 XXXX
REGISTERED - COMBINED SECTION 8 (10-YR) & SEC. 9 FILED
Sep 4, 2017 89AF
TEAS SECTION 8 & 9 RECEIVED
Sep 4, 2017 E89R
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Sep 25, 2016 REM2
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Oct 29, 2013 NA85
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Oct 29, 2013 C15P
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Oct 21, 2013 NA85
POST REGISTRATION ACTION CORRECTION
Oct 21, 2013 XXXX
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Sep 28, 2013 APRE
REGISTERED - SEC. 8 (6-YR) & SEC. 15 FILED
Sep 24, 2013 815F
TEAS SECTION 8 & 15 RECEIVED
Sep 24, 2013 E815
REGISTERED-PRINCIPAL REGISTER
Sep 25, 2007 R.PR
PUBLISHED FOR OPPOSITION
Jul 10, 2007 PUBO
NOTICE OF PUBLICATION
Jun 20, 2007 NPUB
LAW OFFICE PUBLICATION REVIEW COMPLETED
Jun 7, 2007 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 7, 2007 CNSA
AMENDMENT FROM APPLICANT ENTERED
Jun 7, 2007 ACEC
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 7, 2007 CRFA
ASSIGNED TO LIE
Jun 7, 2007 ALIE
PAPER RECEIVED
May 21, 2007 MAIL
NON-FINAL ACTION E-MAILED
Nov 18, 2006 GNRT
NON-FINAL ACTION WRITTEN
Nov 18, 2006 CNRT
AMENDMENT FROM APPLICANT ENTERED
Oct 26, 2006 ACEC
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 12, 2006 CRFA
PAPER RECEIVED
Oct 12, 2006 MAIL
NON-FINAL ACTION E-MAILED
Apr 10, 2006 GNRT
NON-FINAL ACTION WRITTEN
Apr 10, 2006 CNRT
ASSIGNED TO EXAMINER
Mar 31, 2006 DOCK
NEW APPLICATION ENTERED
Oct 3, 2005 NWAP